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Abstract. The role of tumor cell expression of major
histocompatibility class II (MHCII) has been controversial,
with evidence indicating that tumor cell expression of MHCII
may lead to an anti‑tumor immune response and to tumor cell
apoptosis and that MHCII has pro‑tumorigenic functions. The
cancer genome atlas (TCGA) indicates numerous deleterious
mutations for the highly specific, MHCII transcriptional
activation proteins, RFX5, RFXAP, RFXANK and CIITA.
Also, mutations in the non‑polymorphic, human leukocyte
antigen (HLA)‑DRA gene, which encodes the heavy chain
for the most prominent human MHCII molecule, HLA‑DR,
are common. For many, if not most TCGA cancer datasets,
the MHCII specific mutations do not associate with clinical
outcomes. However, stomach carcinoma represents an
exception, where the data indicate that MHCII‑specific
mutations are associated with a more favorable outcome. These
data raise the question of whether stomach cancer mutations
represent effective haploinsufficiency or whether mutations
that are associated with a favorable outcome occur with other
stomach cancer molecular features that limit the function of
the two alleles that represent these MHCII‑related proteins.
Introduction
The potential impact of MHCII expression on solid tumor cells
received increased interest when it became apparent over two
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decades ago that mutations specific to tumorigenesis interfered
with MHCII induction by interferon‑γ (IFN‑γ) (1‑9). As one
example, a lack of retinoblastoma tumor suppressor protein
leads to over expression of the pro‑proliferative protein, YY1,
which in turn is part of a repressive complex that maintains
histone deacetylase activity at the MHCII promoter, thereby
blocking the assembly of MHCII enhanceosome proteins,
including the highly specific MHCII enhanceosome proteins,
RFXANK, RFXAP, RFX5 and CIITA (10,11). In addition,
Ostrand‑Rosenberg and colleagues (12,13) have established
the negative impact of tumor cell‑MHCII expression on tumor
development, although there remain questions about whether
such a negative impact occurs in a natural state, where there
is the expectation of CLIP expression blocking endogenous
MHCII tumor‑peptide loading, or in the absence of tumor
cell expression of conventional co‑stimulatory molecules.
The apoptotic mechanisms of tumor cell MHCII expression
provide another possible ‘anti‑tumor’ role (14,15).
Data collection methods
Clinical and primary tumor specimen mutation Microsoft
Excel files for the stomach adenocarcinoma (STAD), skin
cutaneous melanoma (SKCM), lung adenocarcinoma (LUAD),
colon adenocarcinoma (COAD), head and neck squamous cell
carcinoma (HNSC) and bladder urothelial carcinoma (BLCA)
cancer sets was downloaded from the TCGA data portal
(dbGaP project approval number 6300). The ‘new tumor event
after initial treatment’ column of the TCGA clinical follow up
file for each cancer dataset was used to categorize barcodes
based on the development of a new tumor or not (Table I, New
Tumor and No Subsequent Tumor, respectively). To obtain
matching barcodes, for the clinical and somatic mutation
files, the barcodes from the primary tumor specimen mutation file were truncated to contain the following characters,
TCGA‑##‑####. Mutation data, including truncated tumor
sample barcodes, human genome organization symbols and
mutation type (nonsynonymous or silent) for HLA‑DRA and
the set of transcription factors (CIITA, RFX5, RFXANK and
RFXAP) associated with MHC Class II were collected for each
cancer dataset. Mutations were assessed using the PROVEAN
web tool (16) The Excel COUNTIF function was used to
obtain the number of MHC Class II coding region mutations
per barcode for the New Tumor and No Subsequent Tumor
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Table I. MHC class II associated mutation data for the six TCGA cancer datasets studied.
TCGA cancer dataset
‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑
STAD SKCM LUAD COAD HNSC BLCA
Number of MHC class II coding region mutations from TCGA
Number of coding region mutations when silent mutations removed
Total sample size from TCGA
Number of CIITA mutations
Number of RFX5 mutations
Number of RFXANK mutations
Number of RFXAP mutations
Number of HLA‑DRA mutations
Total mutations
Number of New Tumor barcodes available for study
Number of No Subsequent Tumor barcodes available for study

47
39
379
16
13
3
1
6
39
74
224

106
65
470
37
6
2
2
18
65
101
182

42
34
542
7
23
1
0
3
34
166
243

39
29
216
8
13
1
2
5
29
48
156

33
25
510
15
5
0
3
2
25
63
215

33
24
395
9
7
1
2
5
24
82
146

Data compiled from SOM file labeled, ‘SOM, MHC Class II’ available at http://universityseminarassociates.com/media/SOM_MHC_Class_
II.pdf. The mutation totals for the five coding regions represent non‑synonymous mutations, i.e., silent mutations removed. STAD, stomach
adenocarcinoma; SKCM, skin cutaneous melanoma; LUAD, lung adenocarcinoma; COAD, colon adenocarcinoma; HNSC, head and neck
squamous cell carcinoma; BLAC, bladder urothelial carcinoma; HLA, human leukocyte antigen; MHC, major histocompatibility complex;
TCGA, The Cancer Genome Atlas.

Table II. The average number of mutations per barcode and statistical comparison of the New Tumor and No Subsequent Tumor sets
TCGA cancer dataset
‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑
STAD
SKCM
LUAD
COAD
HNSC
BLCA
Avg. mutations per barcode for New Tumor group
Avg. mutations per barcode for No Subsequent Tumor group
P‑value comparison of New Tumor and No Subsequent Tumor

0.027
0.138
0.004

0.178
0.137
0.512

0.084
0.062
0.481

0.188
0.109
0.275

0.016
0.042
0.238

0.037
0.110
0.052

Data compiled from SOM file labeled, ‘SOM, MHC Class II’ available at http://universityseminarassociates.com/media/SOM_MHC_Class_
II.pdf. Avg, average; STAD, stomach adenocarcinoma; SKCM, skin cutaneous melanoma; LUAD, lung adenocarcinoma; COAD, colon
adenocarcinoma; HNSC, head and neck squamous cell carcinoma; BLAC, bladder urothelial carcinoma; TCGA, The Cancer Genome Atlas.

groups for each cancer dataset and a statistical comparison
between the groups was conducted. t‑tests were used to obtain
P‑values. P<0.05 was considered to indicate a statistically
significant difference. P‑values were obtained using Microsoft
Excel (Microsoft Corporation, Redmond, WA, USA).
All procedures performed in studies involving human
participants were in accordance with the ethical standards of
the institutional and national research committee and with the
1964 Helsinki declaration and its later amendments or comparable ethical standards. The present study is exempt from
IRB approval and was approved via the National Institutes
of Health, Database of Phenotypes and Genotypes (dbGaP),
project no. 6,300; approval granted to George Blanck.
Results and discussion
TCGA provides a wealth of information regarding mutagenesis in many cancer datasets. To obtain an indication of
mutations that may impact MHCII expression, TCGA was

searched for mutations in RFXAP, RFXANK, RFX5, CIITA
and HLA‑DRA. Other MHCII structural genes were excluded
due to the potential confusion caused by the high level of polymorphisms. Overall, the nonsynonymous mutation rate for the
following TCGA datasets, for the above collection of MHCII
specific proteins, was ~8‑9%: STAD, SKCM, LUAD, COAD,
HNSC and BLCA.
The opportunities for linking TCGA clinical information, particularly negative vs. positive outcomes, to particular
mutations remains limited, largely owing to the minimal
overlap of barcodes (patient samples) for mutation results
and clinical information. However, it is possible to attempt to
correlate mutation results with either no‑subsequent tumor or
new‑tumor for the above cancer datasets, particularly due to the
relatively high number of barcodes available representing this
distinction (Table I). Of the six TCGA datasets representing a
substantial number of mutations and no‑subsequent tumor and
new‑tumor cases, only the stomach cancer datasets (STAD)
demonstrated a correlation with the MHCII specific mutations,
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namely an association of more mutations with no‑subsequent
tumor (Table II). Of thirty‑one mutations that were in the
STAD no‑subsequent tumor group, 21 were assessable by the
PROVEAN (17) web tool, of which 9 were deleterious and 12
were neutral. The two mutations that were in the new‑tumor
group were assessable by PROVEAN, revealing that 1 was
deleterious and 1 was neutral.
As aforementioned, solid tumor cell expression of MHCII
has led to contradictory impressions as to whether MHCII
facilitates or inhibits solid tumor development. The above data
support the former possibility, but no doubt there are a number
of circumstances in which the impact of solid tumor expression
of MHCII may have varying effects on tumor progression. For
example, varied solid tumors may be affected differently by
constitutive MHCII expression or MHCII induction by IFN‑γ.
Furthermore, MHCII expression may have different impacts
at different stages of tumorigenesis. The issue of the variable
impacts of immune function spans the consideration of the
role of the immune system in tumor development. Immune
checkpoint inhibitors have had great positive benefits for at
least a subset of patients (18), yet in other settings, evidence
indicates that inflammation, particularly chronic inflammation, is associated with tumor development (19,20).
The negative impact of MHCII expression on solid tumor
cells may include induction of T‑cell anergy (21), due to lack
of costimulatory molecules, but a previous study indicates
that non‑professional antigen presenting cells, including solid
tumor cells, are able to employ substitute co‑stimulatory
molecules such as ICAM1 (22). Another potential explanation
for a negative impact of MHCII expression is the possibility
that MHCII facilitates T‑cell engulfment by solid tumor
cells (23,24).
In conclusion, the current study indicates that, at least in
certain situations, the expression of MHCII on tumor cells
may represent a negative prognosis. Such a conclusion calls
into question scenarios where MHCII‑based interactions with
the immune system would facilitate an anti‑tumor immune
response.
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